References
- Ebers GC. Optic neuritis and multiple sclerosis. Arch Neurol. 1985;42(7):702–704. doi:10.1001/archneur.1985.04060070096025.
- Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727–732. doi:10.1001/archneur.65.6.727.
- Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727–739. doi:10.1016/S1474-4422(10)70094-6.
- Rodriguez M, Siva A, Cross SA, O’brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted county, Minnesota. Neurology. 1995;45(2):244–250. doi:10.1212/wnl.45.2.244.
- Brex PA, Ciccarelli O, O’riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158–164. doi:10.1056/NEJMoa011341.
- Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol. 2005;252(4):396–402. doi:10.1007/s00415-005-0655-9.
- Van Rossum G, Drake FL. Python 3 Reference Manual. Scotts Valley, California, US: CreateSpace; 2009.
- Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139(6):1101–1108. doi:10.1016/j.ajo.2005.01.031.
- Voss E, Raab P, Trebst C, Stangel M. Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. Ther Adv Neurol Disord. 2011;4(2):123–134. doi:10.1177/1756285611398702.
- Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handb Clin Neurol. 2014;122:269–290. doi:10.1016/B978-0-444-52001-2.00011-X.
- Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009;73(19):1543–1550. doi:10.1212/WNL.0b013e3181c0d6e0.
- Pytel V, Matías-Guiu JA, Torre-Fuentes L, et al. Familial multiple sclerosis and association with other autoimmune diseases. Brain Behav. 2018;8(1):e00899. doi:10.1002/brb3.899.
- Greenberg BM, Casper TC, Mar SS, et al. Familial history of autoimmune disorders among patients with pediatric multiple sclerosis. Neurol - Neuroimmunol Neuroinflamm. 2021;8(5):e1049. doi:10.1212/NXI.0000000000001049.
- Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26(6):349–355. doi:10.1053/j.sempedsurg.2017.10.003.
- Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25–36. doi:10.1038/nrneurol.2016.187.
- Minden SL, Frankel D, Hadden L, Hoaglin DC. Access to health care for people with multiple sclerosis. Mult Scler. 2007;13(4):547–558. doi:10.1177/1352458506071306.
- Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? Neurology. 2015;84(21):2185–2192. doi:10.1212/WNL.0000000000001608.
- Eccles A. Delayed diagnosis of multiple sclerosis in males: may account for and dispel common understandings of different MS “types. Br J Gen Pract. 2019;69(680):148–149. doi:10.3399/bjgp19X701729.
- Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389–397. doi:10.1016/S0140-6736(07)61194-5.
- Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18(10):973–980. doi:10.1016/S1474-4422(19)30151-6.